Andreas Müller

669 total citations
21 papers, 380 citations indexed

About

Andreas Müller is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Andreas Müller has authored 21 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Andreas Müller's work include Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (4 papers). Andreas Müller is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (4 papers). Andreas Müller collaborates with scholars based in Switzerland, Germany and Chile. Andreas Müller's co-authors include Roger von Moos, Silva Hečimović, Iskra Petković, Krešimir Pavelić, Ingeborg Barišić, Sandro Anchisi, Ivo Barić, Christoph Rochlitz, Rodney J. Scott and Geoffrey Delmore and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Andreas Müller

19 papers receiving 371 citations

Peers

Andreas Müller

ONCOL

DERMA

GENET

Brigitte Coras Germany

Melinda Jen United States

Patrick W. Blake United States

Said Abdou Egypt

Luíz Fernando Bleggi Torres Brazil

Eun Ji Kwon United States

Prashanta Shrestha Japan

Jung Won Kang South Korea

Flávia Caló de Aquino Xavier Brazil

Kai‐Lin Yan China

Brigitte Coras Germany

Andreas Müller

67 ×0.5

ONCOL

100 ×1.2

119 ×1.7

DERMA

67 ×1.1

GENET

36 ×0.8

Citations per year, relative to Andreas Müller Andreas Müller (= 1×) peers Brigitte Coras

Countries citing papers authored by Andreas Müller

Since Specialization

Citations

This map shows the geographic impact of Andreas Müller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Müller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Müller more than expected).

Fields of papers citing papers by Andreas Müller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Müller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Müller. The network helps show where Andreas Müller may publish in the future.

Co-authorship network of co-authors of Andreas Müller

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Müller. A scholar is included among the top collaborators of Andreas Müller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Müller. Andreas Müller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rothgiesser, Karin, W. Schönfeld, Roger von Moos, et al.. (2025). Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 25(6). 583–588. 1 indexed citations

Rothgiesser, Karin, Qiyu Li, Hanne Hawle, et al.. (2022). SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. SHILAP Revista de lepidopterología. 2(1). 9–18. 1 indexed citations

Vetter, Marcus, Karin Rothgiesser, Hanne Hawle, et al.. (2019). SAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer. Annals of Oncology. 30. iii52–iii52. 2 indexed citations

Biskup, Ewelina, Céline Montavon, Andreas Müller, et al.. (2019). Pertuzumab (P) as ≥ second-line therapy for HER2-positive metastatic breast cancer (mBC): Swiss clinical experience. Annals of Oncology. 30. iii57–iii57.

Huober, Jens, Patrik Weder, Corinne Veyret, et al.. (2018). PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207). Annals of Oncology. 29. viii93–viii93. 5 indexed citations

Rochlitz, Christoph, Roger von Moos, Jürg Bernhard, et al.. (2016). SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC Cancer. 16(1). 780–780. 40 indexed citations

Matter‐Walstra, Klazien, et al.. (2015). Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0. Cancer Research. 75(9_Supplement). P1–10. 2 indexed citations

Templeton, Arnoud J., Karin Ribi, Christian Surber, et al.. (2014). Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). The Breast. 23(3). 244–249. 19 indexed citations

Betticher, Daniel, Geoffrey Delmore, Sandro Anchisi, et al.. (2013). Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Supportive Care in Cancer. 21(9). 2565–2573. 51 indexed citations

10.

Hein, Alexander, Falk C. Thiel, Christian Bayer, et al.. (2012). Hormone replacement therapy and prognosis in ovarian cancer patients. European Journal of Cancer Prevention. 22(1). 52–58. 20 indexed citations

11.

Huober, Jens, Michaël Baumann, Christoph Rochlitz, et al.. (2011). Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. Oncology. 81(3-4). 160–166. 8 indexed citations

12.

Boecken, Gerhard, Cord Sunderkötter, Christian Bogdan, et al.. (2011). Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 9(s8). 1–51. 60 indexed citations

13.

Rochlitz, Christoph, Thomas Ruhstaller, Christian Spirig, et al.. (2010). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of Oncology. 22(1). 80–85. 21 indexed citations

14.

Niedrist, Dunja, Franziska Joncourt, Gábor Mátyás, & Andreas Müller. (2009). Severe phenotype with cis‐acting heterozygous PMP22 mutations. Clinical Genetics. 75(3). 286–289. 4 indexed citations

15.

Müller, Andreas. (2009). Impfungen in der Tropen‐ und Reisemedizin. Hintergrundinformationen für die Beratung. Pharmazie in unserer Zeit. 39(1). 54–61.

16.

Moos, Roger von, et al.. (2009). 5019 Pegylated liposomal doxorubicin and Bevacizumab as first-line therapy for locallyrecurrent or metastatic breast cancer – a multicenter, single-arm phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). European Journal of Cancer Supplements. 7(2). 266–266. 1 indexed citations

17.

Manegold, C., N. Thatcher, C. Kortsik, et al.. (2005). A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): Update on quality of life (QoL), toxicity, and costs. Journal of Clinical Oncology. 23(16_suppl). 7057–7057. 1 indexed citations

18.

Hečimović, Silva, Ingeborg Barišić, Andreas Müller, et al.. (1997). Expand Long PCR for fragile X mutation detection. Clinical Genetics. 52(3). 147–154. 39 indexed citations

19.

Dobbie, Zuzana, R Ammann, Jürgen Roth, et al.. (1994). Mutational analysis of the first 14 exons of the adenomatous polyposis coli (APC) gene. European Journal of Cancer. 30(11). 1709–1713. 40 indexed citations

20.

Schmid, H., et al.. (1988). CA 15-3 und CEA als Tumormarker zur Rezidivdiagnostik beim Mammakarzinom. Geburtshilfe und Frauenheilkunde. 48(5). 309–312. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact